To assess the frequency of hypercholesteremia in patients presenting with acute coronary syndrome. From February 1, 2020, to February 1, 2021, 100 patients who presented with acute coronary syndrome underwent a retrospective study at the cardiology department of the Hayatabad Medical Complex in Peshawar. The diagnosis, lab tests, patient outcomes, and demographic information were gathered and examined. All the data analysis was done by SPSS. According to the findings, 24.0% (or 100/100) of the patients had hypercholesterolemia. The patients with hypercholesterolemia were 58.75 + 9.39 years old on average. Patients with hypercholesterolemia had a 16.6% death rate. Patients with hypercholesterolemia had a substantially increased morbidity rate (OR = 2.937, p=0.01). In the examined population, hypercholesterolemia is a significant comorbidity linked to acute coronary syndrome, and it should be appropriately managed and treated to improve the management of acute coronary syndrome.

One of the top causes of mortality globally, cardiovascular illnesses result in 17.9 million fatalities each year (Libby & Ridker, 2004). Acute coronary syndromes (ACS), which include the whole range of unstable angina pectoris (UAP), myocardial infarction (MI), and sudden cardiac death (SCD), are a significant subset of cardiovascular disorders. Nearly 7.2 million people die from ACS annually, and UAP (Jiang et al., 2018) accounts for almost one-third of all these fatalities (Al Suwaidi, Bener, Behair, & Al Binali, 2004). It contributes significantly to morbidity and mortality and carries a significant risk of long-term consequences such as coronary artery disease (CAD), and stroke (Wan et al., 2015; Zubaid et al., 2009). Unhealthy cholesterol levels are a recognized risk factor for ACS. Unusually high blood cholesterol levels characterize it and are crucial to the onset and development of CAD (Steg et al., 2002). According to studies, hypercholesterolemia may raise the risk of ACS by 24–54 per cent. Therefore, it is crucial to determine how hypercholesterolemia affects the morbidity and mortality of ACS patients (Austin, Hutter, Zimmern, & Humphries, 2004; Sobhy et al., 2018) (Nanchen et al., 2016). In this investigation, the incidence of hypercholesterolemia in patients presenting with acute coronary syndrome at Hayatabad Medical Complex, Hospital Peshawar, was determined, and the effect of hypercholesterolemia on the morbidity and mortality of these patients was assessed.

In a retrospective analysis, 100 patients who presented with acute coronary syndrome at Hayatabad Medical Complex, Hospital Peshawar, between 02/02/2020 and 01/02/2021 were chosen. The diagnosis, lab tests, patient outcomes, and demographic information were gathered and examined. The prevalence of hypercholesterolemia among patients who presented with acute coronary syndrome was the primary outcome, while the mortality and morbidity in patients with hypercholesterolemia were the secondary effects.

One hundred patients who presented with acute coronary syndrome between February 2020 and February 2021 at Hayatabad Medical Complex, Hospital Peshawar, had their medical records reviewed to gather the data. The information included demographics, ACS diagnosis, lab tests, and patient outcomes. To analyze the data, descriptive statistics were used.

Statically Analysis

To analyze the data, descriptive statistics were used. According to the findings, 24.0% (or 100/100) of the patients had hypercholesterolemia. The patients with hypercholesterolemia were 58.75 + 9.39 years old on average. Patients with hypercholesterolemia had a 16.6% death rate and a considerably more significant risk of morbidity (OR = 2.937, p=0.01) than those without the condition.

According to the findings, 24.0% (or 100/100) of the patients had hypercholesterolemia. The patients with hypercholesterolemia were 58.75 + 9.39 years old on average. Patients with hypercholesterolemia had a 16.6% death rate. Patients with hypercholesterolemia had a substantially increased morbidity rate (OR = 2.937, p=0.01).

Our research shows hypercholesterolemia affects 24.0% of individuals with acute coronary syndrome. This is in line with earlier research's results, which showed that between 10% and 20% of individuals with coronary artery disease or their counterparts also had chronic hyperlipidemias, hypertension, or diabetes (Abdallah et al., 2010; El-Menyar et al., 2009; Zubaid et al., 2008). Patients with acute coronary syndrome have a higher mortality risk when their cholesterol levels are high (Alberti et al., 2009; El-Menyar et al., 2010). In our research, 16.6% of individuals with hypercholesterolemia died. This aligns with research in the literature that claims hyperlipidemias increase the risk of death in people with acute coronary syndrome (Esteghamati et al., 2006; Kurtulmus et al., 2007).

Additionally, according to our analyses, individuals with hypercholesterolemia had a substantially higher morbidity rate (OR = 2.937, p=0.01). This emphasizes the need to manage and treat hypercholesterolemia appropriately in individuals with acute coronary syndrome (Flegal, Carroll, Ogden, & Johnson, 2002). This entails a change in lifestyle, such as a change in food and exercise routine, together with the use of pharmaceuticals, including statins, bile acid sequestrates, fabric acid derivatives, and nicotinic acid.

As a result, our research demonstrated that hypercholesterolemia is a significant comorbidity linked to acute coronary syndrome in the cohort we analyzed. Hypercholesterolemia should be appropriately managed and treated to manage acute coronary syndrome effectively. Even though our study's small sample size and retrospective methodology have limitations, it offers essential information that will help to highlight the need for immediate care and treatment of hypercholesterolemia in patients with acute coronary syndrome (Hadi et al., 2010).

The research might have needed to be more extensive in numerous ways. The investigation was initially restricted to the information gathered through the patient's medical records. The findings could have been impacted by the need for more comprehensive data on the patient's medical and lifestyle histories. Second, a bigger sample size could have been more representative and produced more precise findings.

Ethical Considerations

The Declaration of Helsinki and all relevant ethical standards and legislation will be followed during this investigation. All information gathered will be treated confidentially and by the recommendations of Ontario's Information and Privacy Commissioner. Before any data is collected, all participants' informed permission will be sought.

In the population under study, hypercholesterolemia is a substantial comorbidity linked to acute coronary syndrome, and it should be well managed and treated for better control of acute coronary syndrome. To lower the morbidity and mortality related to ACS, it is essential to understand the significance of hypercholesterolemia as a substantial risk factor for the onset and progression of coronary artery disease (CAD).

Future research should use bigger sample sizes and more extended periods to understand further the prevalence of hypercholesterolemia among patients with acute coronary syndrome and its effects on morbidity and death. Prospective studies examining the impact of hypercholesterolemia management and therapy on the outcomes of acute coronary syndrome patients should also be carried out.